Acceleron Pharma is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics to treat diseases. Co.'s research focuses on natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta, or TGF-beta, protein superfamily. By combining Co.'s discovery and development capabilities, including its proprietary knowledge of the TGF-beta superfamily, and its internal protein engineering and manufacturing capabilities, Co. generates therapeutic candidates, all of which encompass potential mechanisms of action. Co. has focused and prioritized its research and development activities within pulmonary and hematology. We show 35 historical shares outstanding datapoints in our coverage of XLRN's shares outstanding history.
Understanding the changing numbers of XLRN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like XLRN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching XLRN by allowing them to research XLRN shares outstanding history
as well as any other stock in our coverage universe. |
Free XLRN Email Alerts:
Video: Shares Outstanding Importance
